Today's Trade: Sell Euro Currency Futures as the Dollar Heats Up on China Tariff Relief
September Euro currency futures (E6U25) present a selling opportunity on more price weakness.
See on the daily bar chart for the September Euro currency futures that prices are trending lower and early this week hit a four-week low. See, too, that the shorter-term moving averages I follow (9- and 18-day) are in a bearish posture as the red 9-day is below the green 18-day and both lines are trending down.
Fundamentally, the U.S.-China trade war is starting to thaw following the weekend trade talks between the two nations that produced positive results and a 90-day delay in most trade tariffs against each other. That's more bullish for the U.S. dollar index ($DXY) than it is for the Euro currency. Also, U.S. economic data recently has been mostly upbeat. And this week, marketplace odds of the Federal Reserve cutting interest rates in June dropped significantly. That's also greenback-bullish.
A price move in the September Euro currency futures below chart support at this week's low of 1.1158 would become a selling opportunity. The downside price objective would 1.0600, or below. Technical resistance, for which to place a protective buy stop just above, is located at 1.1400.
IMPORTANT NOTE: I am not a futures broker and do not manage any trading accounts other than my own personal account. It is my goal to point out to you potential trading opportunities. However, it is up to you to: (1) decide when and if you want to initiate any trades and (2) determine the size of any trades you may initiate. Any trades I discuss are hypothetical in nature.
Here is what the Commodity Futures Trading Commission (CFTC) has said about futures trading (and I agree 100%):
Trading commodity futures and options is not for everyone. IT IS A VOLATILE, COMPLEX AND RISKY BUSINESS. Before you invest any money in futures or options contracts, you should consider your financial experience, goals and financial resources, and know how much you can afford to lose above and beyond your initial payment to a broker. You should understand commodity futures and options contracts and your obligations in entering into those contracts. You should understand your exposure to risk and other aspects of trading by thoroughly reviewing the risk disclosure documents your broker is required to give you.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
38 minutes ago
- Globe and Mail
Cardiovascular Tailwind Boosts BSX: Here's How to Play the Stock
Boston Scientific BSX, a prominent global player in cardiovascular technology, is well-positioned to capitalize on the robust expansion of the cardiovascular devices market. According to a MarketsandMarkets report, this market was valued at $72.83 billion in 2023 and is expected to witness a strong CAGR of 7.3% between 2024 and 2029. With its portfolio of Cardiology and Peripheral Interventions products, Boston Scientific is set to benefit significantly from this upward trend. The booming cardiovascular devices market, driven by aging demographics, minimally invasive procedures, and tech innovation, is propelling Boston Scientific's top-line growth, product leadership and stronger profitability. These tailwinds were clearly reflected in the company's robust first-quarter 2025 performance and raised full-year 2025 guidance. In the past year, Boston Scientific's shares have skyrocketed roughly 31.8%, outpacing the broader Medical Product industry and the S&P 500 benchmark, which have improved about 8.9% and 11.9%, respectively. During this time, Boston Scientific has also outpaced key peers such as Abbott Laboratories ABT and Medtronic MDT. While Abbott, known for its structural heart, cardiac rhythm management, and diagnostics products, gained 24.2%, Medtronic, known for heart valves and coronary stents, advanced 5.1%. BSX 1 Year Price Comparison Major Tailwinds Driving BSX Stock Strong Q1: In the first quarter of 2025, Boston Scientific's revenues were up 22.2% on an operational basis (at a constant exchange rate or CER). The Cardiovascular segment sales were up 26.2% year over year. Within this, Cardiology and Peripheral Interventions businesses' sales grew 31.2% and 7.4%, respectively, year over year. U.S. revenues rose 31%, driven by double-digit growth in most business units. Japan and China also delivered strong results, particularly in EP. Boston Scientific reported adjusted earnings per share (EPS) of $0.75, up 34% year over year. The company's revenues and EPS rose due to exceptional top-line growth across key franchises, especially in EP and structural heart, combined with improved margin performance and disciplined cost management. Cardiovascular Steals Spotlight: Boston Scientific's Electrophysiology business is rapidly expanding its global market share, with first-quarter 2025 organic growth surging 145%, positioning BSX as the number two player in the space. This growth is largely driven by strong commercial adoption of FARAPULSE, the company's flagship Pulsed Field Ablation ('PFA') system, which is gaining traction through global demand, new account expansions, and ongoing clinical studies like AVANT GUARD and Elevate PF. Meanwhile, Boston Scientific's structural heart portfolio is also performing well, with WATCHMAN sales up 24% year over year, aided by DRG-enabled procedural growth. Next-gen versions — WATCHMAN FLX and FLX Pro — are accelerating adoption, while trials like CHAMPION-AF and OPTION A aim to expand the device's global market potential. Boston Scientific's 2025 Outlook Looks Promising For full-year 2025, Boston Scientific raised its organic revenue growth guidance to 12- 14% (from 10-12%) and now expects adjusted EPS of $2.87-$2.94, representing 14-17% year-over-year growth. Reported revenue growth is projected at 15-17%, including contributions from recent acquisitions like Axonics and Intera Oncology. Adjusted operating margin is expected to expand 50-75 basis points, driven by strong product mix, notably FARAPULSE and WATCHMAN, and cost efficiencies. Segmentally, Cardiology continues to lead growth, with Endoscopy and Neuromodulation expected to outperform markets and Urology affected modestly by supply constraints. Estimates for BSX Heading North The Zacks Consensus Estimate for Boston Scientific's 2025 sales and EPS implies a year-over-year improvement of 16.4% and 15.9%, respectively. The bottom-line estimates have moved northward in the past 60 days. BSX's Downsides Boston Scientific continues to face a challenging business environment, thanks to industry-wide macroeconomic pressures, including geopolitical tensions, global supply-chain disruptions, and labor market instability. International conflicts and retaliatory trade actions have increased global risks, while volatile financial markets and fluctuating prices for goods and services are squeezing profitability. Sustained macroeconomic pressures may make it more difficult for the company to manage operating expenses effectively. Tariffs are expected to have a $200 million impact in 2025, which, although planned to be offset through sales growth, cost controls and FX benefits, underscores the heightened complexity of the current environment. BSX Stock Valuation With a forward five-year price-to-earnings (P/E) of 33.31X, Boston Scientific's shares are trading at a premium compared with the industry average of 21.29X. It has a Value Score of D at present. P/E Forward Twelve Months (F12M) Meanwhile, MDT's five-year price-to-earnings (P/E) of 15.63X is lower than the industry average. How to Play BSX Stock? Considering Boston Scientific's strong operational performance, leadership in fast-growing cardiovascular segments like Electrophysiology and Structural Heart, and promising pipeline of developments, the company is clearly executing well on both growth and profitability fronts. With projected double-digit revenue and earnings growth, BSX is poised to continue delivering shareholder value, even amid a complex macroeconomic backdrop and tariff headwinds. The stock has excelled both the industry and its peers, and its estimates are likely to continue to trend upward in the near term. Henceforth, the current BSX shareholders may find it prudent to stay invested. Boston Scientific carries a Zacks Rank #3 (Hold) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report
Globe and Mail
39 minutes ago
- Globe and Mail
Onfolio Holdings Inc. Launches Referral Partner Program to Accelerate Adoption of AI Visibility Services
WILMINGTON, Del., June 10, 2025 (GLOBE NEWSWIRE) -- Onfolio Holdings Inc. (Nasdaq: ONFO, ONFOW) (OTCQB: ONFOP) ('Onfolio' or the 'Company') today announced the official launch of its Referral Partner Program to support the rapid growth of its Generative Engine Optimization (GEO) business. The program offers recurring income and long-term upside to professionals who refer clients to Pace Generative LLC, Onfolio's GEO subsidiary, which helps businesses gain visibility in AI-generated answers from tools like ChatGPT, Gemini, Claude, Grok, and Perplexity. For Onfolio, the program should help to capture the demand and scale revenues significantly faster. Generative Engine Optimization (GEO) is a fast-emerging discipline that positions businesses inside AI-generated responses, rather than simply helping them rank in traditional search engines. When prospective clients ask tools like ChatGPT, 'Who's the best cosmetic surgeon in Miami?' or 'Which estate planning firm in NYC is most reputable?', GEO helps to determine whether a business is mentioned in that real-time answer. 'With the way people now search for trusted services, the brands that show up in AI answers will win the next decade,' said Dominic Wells, CEO of Onfolio. 'Our mission is to ensure that great companies don't get left behind - and our referral partners will be essential to helping us scale that impact.' 'AI is now the first stop for answers,' Wells continued. 'If a company isn't cited, it's not just ranked lower, it's invisible. GEO addresses that. And our referral program allows trusted professionals to help their clients while building a new revenue stream for themselves.' For more information about Pace Generative LLC, visit For more information about our referral program, visit or contact Michael Carwile at partners@ About Onfolio Holdings Inc. Onfolio acquires, operates, and scales a diversified portfolio of digital companies. The Company focuses on businesses with strong cash flows, long-term growth potential, and experienced leadership—or those that can be effectively managed by Onfolio's in-house team. By targeting under-optimized businesses with untapped potential, Onfolio adds value through operational expertise, strategic guidance, and advanced technologies. For more information, visit www. Safe Harbor Statement The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continues," "estimates," "projects," "intends," and similar expressions. Examples of forward-looking statements include, among others, statements we make regarding expected operating results, such as revenue growth and earnings, and strategy for growth and financial results. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing new customer offerings, changes in customer order patterns, changes in customer offering mix, continued success in technological advances and delivering technological innovations, delays due to issues with outsourced service providers, those events and factors described by us in Item 1.A "Risk Factors" in our most recent Form 10-K and Form 10-Q, other risks to which our Company is subject, and various other factors beyond the Company's control. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
National Post
43 minutes ago
- National Post
WealthTech Disruptor, OneVest Recognized for Innovation and Market Impact with Dual Finalist Honors at 2025 Wealthies Awards
Article content NEW YORK — Following its successful Series B funding round led by Salesforce Ventures, OneVest is redefining WealthTech and bringing its transformative, full-stack wealth management platform to financial institutions across the US. This strategic growth underscores OneVest's commitment to reshaping the future of wealth management with technology that enables seamless, scalable, and intelligent investing experiences for Advisor, Client and Home Office. Article content As the industry evolves, OneVest's modular platform is helping RIAs, banks, asset managers and insurance companies modernize how they deliver wealth management solutions and services, driving operational efficiency, enhancing client engagement, and reducing time to market. Article content Article content Recognized by the Industry Article content That momentum has earned OneVest finalist recognition in two categories for the 2025 Informa Connect Wealth Management Industry Awards: Article content These honors validate OneVest's leadership in delivering cutting-edge solutions that simplify complex processes and enhance advisor productivity. Article content A standout innovation is Next Best Action Powered by AI, a feature that delivers real-time, proactive recommendations to advisors. By surfacing intelligent, context-aware prompts, the tool helps wealth managers engage clients more effectively, take timely action, and ultimately drive better financial outcomes. It is part of OneVest's recently announced Enhanced AI suite and a key differentiator in the wealthtech space. Article content Furthering this leadership in innovation, OneVest will be featured at Wealth Management EDGE, the industry's leading thought leadership event. Co-Founder and CEO Amar Ahluwalia will speak on the AI Assembly Track on the 'Work Smarter, Not Harder: AI's Role in Operational Excellence' panel held on Tuesday, June 10 at 2:50–3:30 PM ET. Article content The session will explore how firms can harness AI to enhance operations and empower advisors in an increasingly complex environment. Orchestrating the Entire Wealth Stack Article content OneVest's platform is designed with open architecture at its core, enabling effortless integration with third-party systems across compliance, custodial services, CRM, and more. This universal orchestration allows financial institutions to customize and control their entire tech stack without compromising scale or performance. Article content An important part of wealth management solutions is the integrations to the custodian ecosystem. OneVest continues to deepen relationships with leading custodians and infrastructure providers, including Charles Schwab, Envestnet, APEX, DriveWealth, Hilltop, Plaid and many more, offering clients unmatched flexibility and connectivity across their operations. Article content These integrations accelerate time-to-value for new OneVest clients by significantly reducing implementation effort. With built-in connectivity to leading custodians and infrastructure providers, firms can onboard quickly, minimize manual setup, and immediately deliver a modern, unified experience to both advisors and end clients—without heavy development work. Article content OneVest is the right choice for modern RIA firms looking to scale fast by attracting top advisor talent. Article content Advisor transitions are often messy, manual, and resource-intensive, both for the incoming advisor and the firm. Many RIAs rely on fragmented processes that create bottlenecks, increase compliance risk, and slow down AUM transfers. For advisors, the operational burden and uncertainty of joining a new firm can be a major deterrent, and for firms, it's a costly and inconsistent experience that strains transition teams and jeopardizes client retention. Article content OneVest solves this with a fully digital, end-to-end advisor onboarding experience. Configurable workflows, embedded compliance tools, and integrated data infrastructure reduce manual lift, eliminate redundant processes, and accelerate time to revenue. Advisors can bring over their book smoothly, while firms maintain full visibility and control. For growing RIAs, this means faster ramp-up times, fewer errors, and a standardized onboarding journey aligned with firm policies and brand expectations, helping firms recruit top talent and scale with speed. Article content About OneVest Article content OneVest is a financial technology company on a mission to Power the World's Wealth. It offers an end-to-end wealth management platform, from client onboarding, to portfolio management, to analytics and beyond. OneVest's software was built to be modular, allowing financial institutions to fill gaps in their process depending on their needs. With backing from leading investors such as Salesforce, Deloitte, Allianz, TIAA, OMERS, Fin Capital, FJ Labs and many more, OneVest is positioned at the forefront of wealth management innovation. Article content Article content Article content Article content
